Danish biotechnology company Genmab A/S (CPH:GMAB) announced on Monday that it will assume full responsibility for the continued development and potential commercialisation of acasunlimab (GEN1046).
Genmab's German partner BioNTech SE (Nasdaq:BNTX) has decided to exit the development programme. Genmab will pay milestones and royalties to BioNTech.
The companies' broader collaboration remains intact.
Acasunlimab is an investigational PD-L1x4-1BB bispecific antibody fusing Genmab's proprietary DuoBody technology platform and BioNTech's proprietary immunomodulatory antibodies. It is currently being investigated in three clinical trials: a Phase 1/2 safety and PK trial in patients with multiple solid tumours; a Phase 1 dose escalation trial in patients with advanced solid tumours in Japan; and a randomised Phase 2 safety and efficacy trial with acasunlimab as a monotherapy and in combination with pembrolizumab in patients with non-small cell lung cancer (NSCLC) who have failed previous standard of care treatments with immune checkpoint inhibitors.
Genmab plans to initiate a Phase 3 study for acasunlimab in the second half of the year.
This change is not expected to impact Genmab's 2024 financial guidance.
Sanofi and J&J discontinue phase 3 study of E. coli vaccine candidate
OnCusp Therapeutics' CUSP06 receives US FDA Fast Track Designation
MimiVax reports positive interim analysis of SurVaxM Phase 2b clinical trial
Akeso enrols first patient in cadonilimab Phase 3 clinical trial
NKGen Biotech receives US FDA Fast Track designation for troculeucel in Alzheimer's treatment
Neuphoria Therapeutics to receive USD15m milestone payment from Merck
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Royalty Pharma to invest up to USD250m in Biogen's lupus treatment
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Lytix Biopharma secures US patent allowance for LTX-315 clinical programme
GenSight Biologics reports positive five-year resultsfor LUMEVOQ gene therapy
IXICO's AI platform validated in Huntington's Disease research
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Spinogenix reveals topline results from Phase 2 study in Fragile X syndrome
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval